Regenxbio Inc (RGNX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Regenxbio Inc (RGNX) has a cash flow conversion efficiency ratio of -0.867x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-62.24 Million) by net assets ($71.77 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Regenxbio Inc stock valuation for the company's overall valuation and market capitalisation.
Regenxbio Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Regenxbio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Regenxbio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Regenxbio Inc ranked by their cash flow conversion efficiency. Explore Regenxbio Inc (RGNX) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Elior SCA
PA:ELIOR
|
0.089x |
|
Beijing Sanlian Hope Shin-Gosen Technical Service Co Ltd
SHE:300384
|
-0.003x |
|
WINBO-Dongjian Automotive Technology Co. Ltd.
SHE:300978
|
0.083x |
|
Nexpoint Residential Trust Inc
NYSE:NXRT
|
0.084x |
|
Nextdoor Holdings Inc
NYSE:KIND
|
0.007x |
|
Zaptec AS
OL:ZAP
|
0.579x |
|
Tilray Inc
NASDAQ:TLRY
|
-0.023x |
|
Matrix Concepts Holdings Bhd
KLSE:5236
|
0.037x |
Annual Cash Flow Conversion Efficiency for Regenxbio Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Regenxbio Inc from 2013 to 2025. View Regenxbio Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $102.73 Million | $-123.96 Million | -1.207x | -80.97% |
| 2024-12-31 | $259.65 Million | $-173.12 Million | -0.667x | +4.83% |
| 2023-12-31 | $311.74 Million | $-218.41 Million | -0.701x | -74.30% |
| 2022-12-31 | $516.20 Million | $-207.49 Million | -0.402x | -240.36% |
| 2021-12-31 | $764.30 Million | $218.88 Million | 0.286x | +300.10% |
| 2020-12-31 | $377.75 Million | $-54.06 Million | -0.143x | +40.18% |
| 2019-12-31 | $450.20 Million | $-107.70 Million | -0.239x | -216.33% |
| 2018-12-31 | $508.85 Million | $104.65 Million | 0.206x | +164.91% |
| 2017-12-31 | $183.03 Million | $-57.99 Million | -0.317x | -5.54% |
| 2016-12-31 | $161.74 Million | $-48.56 Million | -0.300x | -189.10% |
| 2015-12-31 | $216.81 Million | $-22.52 Million | -0.104x | -124.67% |
| 2014-12-31 | $-5.70 Million | $-2.40 Million | 0.421x | -70.04% |
| 2013-12-31 | $-2.14 Million | $-3.01 Million | 1.406x | -- |
About Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular … Read more